6702-72-3

Usage

Uses

Used in Pharmaceutical Development:
6-(cyclohexylamino)pyrimidine-2,4(1H,3H)-dione is utilized as a key building block for the synthesis of biologically active molecules, contributing to the advancement of new pharmaceutical agents.
Used in Cancer Treatment Research:
In the field of oncology, 6-(cyclohexylamino)pyrimidine-2,4(1H,3H)-dione is studied for its potential therapeutic applications against various types of cancer, offering a new avenue for treatment development.
Used in Neurological Disorder Research:
6-(cyclohexylamino)pyrimidine-2,4(1H,3H)-dione is also being investigated for its possible applications in the treatment of neurological disorders, suggesting a role in the development of neurotherapeutic agents.
Used as an Anti-Inflammatory Agent:
6-(cyclohexylamino)pyrimidine-2,4(1H,3H)-dione has been explored for its anti-inflammatory properties, indicating its potential use in the management of inflammatory conditions.
Used in Enzyme and Receptor Modulation:
Due to its activity on various enzymes and receptors within the body, 6-(cyclohexylamino)pyrimidine-2,4(1H,3H)-dione is of interest in the development of drugs that modulate these biological targets for therapeutic benefit.
Overall, 6-(cyclohexylamino)pyrimidine-2,4(1H,3H)-dione is a chemical entity with a broad spectrum of potential applications across different areas of medical and pharmaceutical research, making it a valuable asset in the pursuit of novel treatments and therapies.

Upstream product

• 4270-27-3 6-chlorouracil 
• 108-91-8 cyclohexylamine 

Downstream Products

• 1448807-59-7 8-chloro-10-cyclohexylpyrimido[4,5-b]quinoline-2,4-dione 

Relevant academic research and scientific papers

Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II

The recently discovered enzyme tyrosyl-DNA phosphodiesterase 2 (TDP2) has been implicated in the topoisomerase-mediated repair of DNA damage. In the clinical setting, it has been hypothesized that TDP2 may mediate drug resistance to topoisomerase II (topo II) inhibition by etoposide. Therefore, selective pharmacological inhibition of TDP2 is proposed as a novel approach to overcome intrinsic or acquired resistance to topo II-targeted drug therapy. Following a high-throughput screening (HTS) campaign, toxoflavins and deazaflavins were identified as the first reported sub-micromolar and selective inhibitors of this enzyme. Toxoflavin derivatives appeared to exhibit a clear structure-activity relationship (SAR) for TDP2 enzymatic inhibition. However, we observed a key redox liability of this series, and this, alongside early in vitro drug metabolism and pharmacokinetics (DMPK) issues, precluded further exploration. The deazaflavins were developed from a singleton HTS hit. This series showed distinct SAR and did not display redox activity; however low cell permeability proved to be a challenge.

Synthesis of substituted uracils by the reactions of halouracils with selenium, sulfur, oxygen and nitrogen nucleophiles under focused microwave irradiation

Under microwave irradiation, the nucleophilic substitution reactions of halouracils with selenium, sulfur, oxygen and nitrogen nucleophiles was complete within several minutes with yields up to 99%. The method using microwave irradiation is superior to th